189 related articles for article (PubMed ID: 37682601)
1. A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers.
Zang J; Lin R; Wen X; Wang C; Zhao T; Jakobsson V; Yang Y; Wu X; Guo Z; Chen X; Zhang J; Miao W
Clin Nucl Med; 2023 Oct; 48(10):861-868. PubMed ID: 37682601
[TBL] [Abstract][Full Text] [Related]
2. [
Lin R; Wang C; Chen S; Lin T; Cai H; Chen S; Yang Y; Zhang J; Xu F; Zhang J; Chen X; Zang J; Miao W
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):535-547. PubMed ID: 37728667
[TBL] [Abstract][Full Text] [Related]
3. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
Çermik TF; Ergül N; Yılmaz B; Mercanoğlu G
Clin Nucl Med; 2022 Apr; 47(4):e333-e339. PubMed ID: 35085165
[TBL] [Abstract][Full Text] [Related]
4. The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.
Shu Q; Deng M; Hu M; Liu M; Chen X; Chen Y; Cai L
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1442-1452. PubMed ID: 36609606
[TBL] [Abstract][Full Text] [Related]
5. First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer.
Wegen S; Roth KS; Weindler J; Claus K; Linde P; Trommer M; Akuamoa-Boateng D; van Heek L; Baues C; Schömig-Markiefka B; Schomäcker K; Fischer T; Drzezga A; Kobe C; Köhler C; Marnitz S
Clin Nucl Med; 2023 Feb; 48(2):150-155. PubMed ID: 36607364
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of [
Li C; Tian Y; Chen J; Jiang Y; Xue Z; Xing D; Wen B; He Y
Eur Radiol; 2023 Apr; 33(4):2779-2791. PubMed ID: 36394603
[TBL] [Abstract][Full Text] [Related]
7. PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using
Pang Y; Zhao L; Meng T; Xu W; Lin Q; Wu H; Zhang J; Chen X; Sun L; Chen H
J Nucl Med; 2023 Mar; 64(3):386-394. PubMed ID: 36215571
[TBL] [Abstract][Full Text] [Related]
8. Superiority of 68Ga-FAPI-04 in Delineation of Soft Tissue and Liver Metastases in Chromophobe Renal Cell Carcinoma for Restaging.
Xie F; Fu L; Zhou W
Clin Nucl Med; 2022 Dec; 47(12):e758-e759. PubMed ID: 36342807
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in the staging and restaging of gastric adenocarcinoma.
Gündoğan C; Kömek H; Can C; Yildirim ÖA; Kaplan İ; Erdur E; Poyraz K; Güzel Y; Oruç Z; Çakabay B
Nucl Med Commun; 2022 Jan; 43(1):64-72. PubMed ID: 34661379
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-FAPI Versus 18F-FDG PET/CT in Evaluating Newly Diagnosed Breast Cancer Patients: A Head-to-Head Comparative Study.
Zheng S; Lin J; Zhu Y; Chen Y; Zhang J; Chen X; Miao W
Clin Nucl Med; 2023 Mar; 48(3):e104-e109. PubMed ID: 36723892
[TBL] [Abstract][Full Text] [Related]
11. Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience.
Elboga U; Sahin E; Cayirli YB; Okuyan M; Aktas G; Haydaroglu Sahin H; Dogan I; Kus T; Akkurd DM; Cimen U; Mumcu V; Kilbas B; Celen YZ
Tomography; 2022 Feb; 8(1):293-302. PubMed ID: 35202189
[TBL] [Abstract][Full Text] [Related]
12. [
Lin R; Lin Z; Chen Z; Zheng S; Zhang J; Zang J; Miao W
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2960-2971. PubMed ID: 35462566
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma.
Guo C; Liu Y; Yang H; Xia Y; Li X; Chen L; Feng Y; Zhang Y; Chen Y; Huang Z
Br J Radiol; 2024 Mar; 97(1156):859-867. PubMed ID: 38290775
[TBL] [Abstract][Full Text] [Related]
15. The performance of
Jiang Y; Wen B; Li C; Tian Y; Xiao Z; Xu K; Xing D; Yu Z; Huang J; Jia J; He Y
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2114-2126. PubMed ID: 36808001
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of
Zhang J; Jiang S; Li M; Xue H; Zhong X; Li S; Peng H; Liang J; Liu Z; Rao S; Chen H; Cao Z; Gong Y; Chen G; Zhang R; Zhang L
Cancer Imaging; 2023 Oct; 23(1):106. PubMed ID: 37899452
[TBL] [Abstract][Full Text] [Related]
17. [
Wu C; Zhang X; Zeng Y; Wu R; Ding L; Xia Y; Chen Z; Zhang X; Wang X
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):194-204. PubMed ID: 36040490
[TBL] [Abstract][Full Text] [Related]
18. Superior Tumor Detection for
Pabst KM; Trajkovic-Arsic M; Cheung PFY; Ballke S; Steiger K; Bartel T; Schaarschmidt BM; Milosevic A; Seifert R; Nader M; Kessler L; Siveke JT; Lueckerath K; Kasper S; Herrmann K; Hirmas N; Schmidt HH; Hamacher R; Fendler WP
J Nucl Med; 2023 Jul; 64(7):1049-1055. PubMed ID: 37024301
[TBL] [Abstract][Full Text] [Related]
19. A comparison of [
Liu N; Wan Q; Wu X; Zhao T; Jakobsson V; Yuan H; Chen X; Zhang J; Zhang W
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1685-1697. PubMed ID: 38246909
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of
Chen X; Wang S; Lai Y; Wang G; Wei M; Jin X; Ding J; Zhang Y; Shi Y; Wang F; Zhu H; Yang Z; Wang X
J Nucl Med; 2023 Sep; 64(9):1399-1405. PubMed ID: 37385675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
